Company intelligence / Profile preview

OrienGene Biotechnology

Ownership: Private
Development stage: Other

Overview

OrienGene's lead program, "OrienX010"—a recombinant human GM-CSF-expressing herpes simplex virus—is in Phase II trials for malignant melanoma. Data from Phase I trials have been presented at major oncology conferences, showing ongoing clinical progress but no published pivotal results yet.

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapyGene therapy
Industry: Biotech

Drug pipeline

1 asset

orienx010

Partnerships

Beijing Bozhiyin T&SSTART Shanghai

Beyond the preview

Go deeper on OrienGene Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OrienGene Biotechnology.

Explore the full profile